SVMPharma Real World Evidence - Overcoming challenges to access in rare disease: A ‘Real World’ perspective. For more information and resources visit us at www.svmpharma.com

1. CONTACT US
enquiry@svmpharma.com
+44(0) 1252 417030
SVMPharma Limited
www.svmpharma.com
For more on RWE visit:
www.svmpharma.com
1. Improving the intelligence of your
data capture: Technology in RWE
2. EMA seeking to make better use of
patient registries to collect high-
quality data on medicines
3. Big Data remains high on EU's
healthcare agenda
RWE messages that you
may have missed out on
(Click on the links below to find out more)
The Orphan Drug Report
reveals that worldwide orphan drug
sales will reach $178bn by 2020.
19.4% of EU orphan designations
are for ultra-rare diseases
‘the real added value of an orphan medicine
can only be demonstrated through the
continuous generation of real-life evidence in
the years following marketing authorisation and
all along the life cycle of the medicine.’
- The rare disease group alliance, EURORDIS
Overcoming challenges to access in rare disease:
A ‘Real World’ perspective
But as number of orphan
drugs increases so will
pricing
Click here to see the reference